Ai-Qin Gu1, Wei-Ming Wang1, Wen-Yi Chen1, Chun-Lei Shi1, Jian-Hong Lu2, Jun-Qing Han3. 1. Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University Shanghai 200030, China. 2. International Medical Care Center, Shanghai General Hospital, Shanghai Jiao Tong University Shanghai 200080, China. 3. Cancer Research and Treatment Center, Shandong Provincial Hospital Affiliated to Shandong University 324 Jingwu Road, Jinan 250021, Shandong, P.R. China.
Abstract
OBJECTIVE: To evaluate the correlation between genetic polymorphisms in x-ray repair cross complementing group 1 (XRCC1) and sensitivity to platinum-based chemotherapy drugs in patients with non-small cell lung cancer. METHODS: Reports published before June 2014 were retrieved from the following databases: China Biology Medicine (CBM), China Academic Journal Full-Text Database (CNKI), China Science and Technology Journal Full-Text Database (VIP), Wanfang Data, PubMed and Excerpta Medica dataBASE (EMBASE). After extracting the data and evaluating the quality, meta-analysis was performed using RevMan5.2 software. RESULTS: A total of 29 studies with 4807 patients were included. Two polymorphisms (Arg399Gln and Arg194Trp) were analyzed. Meta-analysis showed that the efficacy of chemotherapy for patients with the TT genotype [TT vs. CC, OR=1.66, 95% OR=1.66, 95 CI (1.30-2.14)] and the CT genotype [CT vs. CC, OR=1.62, 95% CI (1.35-1.93)] at codon 194 of the XRCC1 gene was significantly higher than that for patients with the CC genotype. The efficacy of chemotherapy for patients with mutant (CT+TT) genotypes was significantly higher than for patients with the wild-type (CC) genotype [TT+CT vs. CC, OR=1.63; 95% CI (1.38-1.92)]. The sensitivity to chemotherapy in patients with the AG genotype at codon 399 of the XRCC1 gene was lower than in patients with the GG genotype [AG vs. GG, OR=0.72, 95% CI (0.55-0.92)] in Chinese population. However, we did not found this association in Caucasus population. CONCLUSION: Genetic polymorphisms in the XRCC1 gene are correlated with sensitivity to platinum-based chemotherapy in patients with non-small cell lung cancer.
OBJECTIVE: To evaluate the correlation between genetic polymorphisms in x-ray repair cross complementing group 1 (XRCC1) and sensitivity to platinum-based chemotherapy drugs in patients with non-small cell lung cancer. METHODS: Reports published before June 2014 were retrieved from the following databases: China Biology Medicine (CBM), China Academic Journal Full-Text Database (CNKI), China Science and Technology Journal Full-Text Database (VIP), Wanfang Data, PubMed and Excerpta Medica dataBASE (EMBASE). After extracting the data and evaluating the quality, meta-analysis was performed using RevMan5.2 software. RESULTS: A total of 29 studies with 4807 patients were included. Two polymorphisms (Arg399Gln and Arg194Trp) were analyzed. Meta-analysis showed that the efficacy of chemotherapy for patients with the TT genotype [TT vs. CC, OR=1.66, 95% OR=1.66, 95 CI (1.30-2.14)] and the CT genotype [CT vs. CC, OR=1.62, 95% CI (1.35-1.93)] at codon 194 of the XRCC1 gene was significantly higher than that for patients with the CC genotype. The efficacy of chemotherapy for patients with mutant (CT+TT) genotypes was significantly higher than for patients with the wild-type (CC) genotype [TT+CT vs. CC, OR=1.63; 95% CI (1.38-1.92)]. The sensitivity to chemotherapy in patients with the AG genotype at codon 399 of the XRCC1 gene was lower than in patients with the GG genotype [AG vs. GG, OR=0.72, 95% CI (0.55-0.92)] in Chinese population. However, we did not found this association in Caucasus population. CONCLUSION: Genetic polymorphisms in the XRCC1 gene are correlated with sensitivity to platinum-based chemotherapy in patients with non-small cell lung cancer.
Authors: Daniela F Giachino; Paolo Ghio; Silvia Regazzoni; Giorgia Mandrile; Silvia Novello; Giovanni Selvaggi; Dario Gregori; Mario DeMarchi; Giorgio V Scagliotti Journal: Clin Cancer Res Date: 2007-05-15 Impact factor: 12.531
Authors: Ivana Sullivan; Juliana Salazar; Margarita Majem; Cinta Pallarés; Elisabeth Del Río; David Páez; Montserrat Baiget; Agustí Barnadas Journal: Cancer Lett Date: 2014-07-25 Impact factor: 8.679
Authors: R de las Peñas; M Sanchez-Ronco; V Alberola; M Taron; C Camps; R Garcia-Carbonero; B Massuti; C Queralt; M Botia; R Garcia-Gomez; D Isla; M Cobo; M Santarpia; F Cecere; P Mendez; J J Sanchez; R Rosell Journal: Ann Oncol Date: 2006-01-11 Impact factor: 32.976
Authors: Aristea Kalikaki; Maria Kanaki; Helen Vassalou; John Souglakos; Alexandra Voutsina; Vassilis Georgoulias; Dimitris Mavroudis Journal: Clin Lung Cancer Date: 2009-03 Impact factor: 4.785